Form 4: Vertex Pharmaceuticals EVP, COO Stuart Arbuckle Reports Stock Sale
SEC Form 4
Stuart Arbuckle, EVP and COO of Vertex Pharmaceuticals, reports the sale of 69 shares of common stock at a price of $430.93 per share.
Summary
- On May 15, 2024, Stuart A. Arbuckle, the EVP and COO of Vertex Pharmaceuticals, sold 69 shares of common stock at $430.93 per share.
- Following the transaction, Mr. Arbuckle directly owns 49,691 shares of Vertex Pharmaceuticals common stock.
- He also indirectly owns 140 shares through a 401(k) plan.
- The sale was executed under a pre-arranged trading plan (Rule 10b5-1) established on February 28, 2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale by an executive under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company.
Industry Context
Executive stock sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. Monitoring executive transactions can provide insights, but should be considered in the context of overall company performance and industry trends.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 02/28/2023 | Date of entry into Rule 10b5-1 trading plan |
| 05/15/2024 | Date of stock sale transaction |
| 05/17/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.